Bio-techne Corp · NASDAQ:TECH
Bio-techne — Investor Presentation (January 2023)
29 slides from Bio-techne's investor presentation, January 2023
Slide 1: Where Science Intersects Innovation
Where Science Intersects Innovation™ Bio-Techne Corporate Presentation | January 2023 Confidential. © 2023 Bio-Techne®. All rights reserved. | 1
Slide 2: Safe Harbor Cautionary Statements
Safe Harbor C A U T I O N A R Y S TAT E M E N T S This presentation contains “forward-looking “expects,” “expect,” “forecast,” “would,” on Form 10-K. We undertake no obligation to statements” within the meaning of the “estimate,” “will,” or similar references to publicly update any forward-looking f
Slide 3: Overview
Overview Confidential. © 2023 Bio-Techne®. All rights reserved. | 3
Slide 4: Business Overview
Business Overview President & CEO Product Portfolio Chuck Kummeth Instruments Services Headquarters 11% 6% Royalties Minneapolis, MN 2% Proteins Antibodies Number of Employees ~3,000 Proteomic Worldwide Presence Immunoassays Analytical 34 Locations Instruments FY2022 Revenues Spatial Molecular $1.1B
Slide 5: FY22 Revenue by Customer Type & Geography
FY22 Revenue by Customer Type & Geography Distributors 15% Asia 17% OEM 15% $1.1B Pharma/ Americas Biotech 48% 59% EMEA Academia 24% 22% OVERVIEW Confidential. © 2023 Bio-Techne®. All rights reserved. | 5
Slide 6: Deploying Five Key Strategies to Drive Profitable Growth
Deploying Five Key Strategies to Drive Profitable Growth OVERVIEW Confidential. © 2023 Bio-Techne®. All rights reserved. | 6
Slide 7: Laying the Foundation for a Sustainable Future
Laying the Foundation for a Sustainable Future Environmental Social Governance Continual progress toward Diverse and inclusive workplace: Board includes: sustainability at largest global manufacturing site: • 50% of global workforce are female • Diverse membership • 52% of scientists are female • De
Slide 8: Financial Results Under Current Leadership
Financial Results Under Current Leadership 22% 421 352 325 364 Actual Organic Growth 17% Organic Growth Adjusted for Covid 246 205 10% 239 244 182 9% 170 ~13% 208 198 144 143 6% 6% 184 190 137 139 ~11% 169 124 4% 3% 4% 0% OVERVIEW 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2013 2014 2015 2016
Slide 9: Our Focus
Our Focus Confidential. © 2023 Bio-Techne®. All rights reserved. | 9
Slide 10: Protein Sciences
Protein Sciences Proteomic Research Reagents Proteomic Analytical Tools Proteins Antibodies Immunoassays Instruments OUR FOCUS Confidential. © 2023 Bio-Techne®. All rights reserved. | 10
Slide 11: Proteomic Research Reagents
Proteomic Research Reagents Total Addressable Market: Proteins Antibodies ~$4B Market Growth: Mid-Single Digit Bio-Techne Market Share: ~10% Bio-Techne Growth: 7%-9% • Proteins sold with optimal bio-activity, • Full length proteins with native protein highest quality, lot to lot consistency structur
Slide 12: Proteomic Analytical Tools
Proteomic Analytical Tools Total Addressable Market: Immunoassays Simple Western Biologics $3B-$4B Market Growth: • Market leading portfolio of • Fully automated western, no • Bioprocessing, two Upper-Single Digit single analyte & multiplex gels, no film applications (CE-SDS and Bio-Techne Market Sh
Slide 13: Expanding Proteomic Analytical Instrument Applications
Expanding Proteomic Analytical Instrument Applications Biologics Simple Western Simple Plex Legacy Expanded Legacy Expanded Legacy Expanded Application Application Application Application Application Application • Protein purity, • Fractionation for mass • Fully automated • Quantitative • Automated
Slide 14: Enabling the Proteomic Revolution
Enabling the Number of Samples Number of Proteins Proteomic Revolution Discovery - High Plex Bio-Techne is the content provider of choice (e.g. antibodies and ligands) that enables high plex proteomic technologies. 10s 100s-1000s Verification & Validation – Secondary Screen & LDT Customizable Lumine
Slide 15: Diagnostics & Genomics
Diagnostics & Genomics Spatial Biology Molecular Diagnostics Diagnostic Reagents & Controls OUR FOCUS Confidential. © 2023 Bio-Techne®. All rights reserved. | 15
Slide 16: Spatial Biology
Spatial Biology Total Addressable Market: ~$2B Market Growth: Low-Double Digit Bio-Techne Market Share: ~5% Bio-Techne Growth: • RNAscope & DNAscope technologies are • Unlike competing technologies, tissue 15%-20% novel in-situ hybridization (ISH) assays morphology is retained, enabling tissue for t
Slide 17: ACD Spatial Biology Tools: Gold Standard for Translational Research
ACD Spatial Biology Tools: The Gold Standard for Translational Research to Clinical Development Discovery – Translational Research Clinical Basic Research Translational Next Generation Biomarker Research & Validation Tissue Dx And CDx Discovery in Spatial Context Single or Multiplex RNA Positioned f
Slide 18: Liquid Biopsies: CTC, cfDNA, & Exosomes
Liquid Biopsies: CTC, cfDNA, & Exosomes Key Properties CTC cfDNA Exosomes Difficult to find Infrequent in early Prevalence within “noise” of Abundant stages of disease contaminating DNA Early Abundance No No Yes Ability to Enrich Yes No Yes or Select Quality of Poor due to High-quality Good Isolated
Slide 19: Exosome Based Liquid Biopsy
Exosome Based Liquid Biopsy ExoDX Prostate Test (EPI) Prostate Cancer Risk Increase Patient ID Men For Active Stratification Compliance Surveillance Validated to risk stratify clinically 92% patient compliance to World Journal of Urology study *Data from Tutrone R, Donovan MJ, Torkler P, Tadigotla V
Slide 20: Emerging Exosome Platform Applications
Emerging Exosome Platform Applications Prostate Cancer Expand Current Colorectal Early Current Portfolio Expansion Markets Detection Test Development Screening Programs EXOSOME DX PLATFORM EXPANSION • Prostate Cancer Expansion • Solid Tumor Mutation Diagnosis Leverage existing urology Launch single
Slide 21: Molecular Products
Molecular Products Total Addressable Market: ~$1B Market Growth: Low-Double Digit Bio-Techne Market Share: <5% Bio-Techne Growth: • Market leading developer and • 14 products currently on the market >20% manufacturer of molecular controls, including carrier screening kits for Fragile genetic carrier
Slide 22: Diagnostic Reagents & Controls
Diagnostic Reagents & Controls Total Addressable Market: $1B-$2B Market Growth: Mid-Single Digit Bio-techne Market Share: ~10% Bio-techne Growth: 5%-7% • Market leading supplier of clinical • >40 years of experience developing and controls, calibrators and kits for the manufacturing diagnostic reage
Slide 23: Wilson Wolf Agreement
Wilson Wolf Agreement GMP Proteins Closed Delivery Announced agreement with Wilson Bag Wolf for potential ownership investment and future acquisition • Wilson Wolf manufactures the G-Rex • Technology currently used by product line, a leading cell culture device ~800 biopharma customers T Cell Media
Slide 24: Cross Company Cell Therapy Workflow Solutions
Cross Company Cell Therapy Workflow Immune Cell Therapy Solutions Fight cancer or clear diseases with manipulated immune cells Regenerative Medicine 1. White blood cells obtained from patient through leukapheresis (Stem Cell Therapy) 2. Antibody-coated beads used to activate the T cells Replace lost
Slide 25: Cross Company Cell & Gene Therapy Portfolio Positioned for Growth
Cross Company Cell & Gene Therapy ~$2B Portfolio Positioned for Growth >$100M FY22 Spatial Genome Media & Proteomic GMP Reagents Wilson Wolf FY32 Biology Engineering Matrices Analytical • GMP Proteins • G-Rex Target OUR FOCUS Tools: • GMP Antibodies • RNAScope • Genome • BME • BaseScope Engineering
Slide 26: Large Addressable End Markets: ~$17B-$21B
Large Addressable End Markets: ~$17B-$21B End Market Market Bio-Techne Bio-Techne Market Markets Size Growth Rate Growth Rate Penetration Proteomic Research Reagents ~$4B Mid-Single Digit 7%-9% ~10% Proteomic Analytical Tools $3B-$4B Upper-Single Digit ~15% >10% Cell Culture & Gene Therapy $3B-$4B >
Slide 27: The Path to $2B
The Path to $2B HIGH-TEENS OG ~50% CAGR ~$2B ~50% CAGR ~18% CAGR ~15% CAGR Portfolio In Low-Teens ~7% • GMP Place To Grow CAGR Normalized OG • ExoDx proteins • GMP culture Revenue From • RNAscope $1.1B • DNAscope Prostate • ExoTRU & media $1.1B In FY22 • GMP Small • Simple • HiPlex • BaseScope Kidne
Slide 28: Thank you
Thank you Confidential. © 2023 Bio-Techne®. All rights reserved. | 28
Slide 29: Confidential. © 2023 Bio-Techne ® . All rights reserved. | 29
Confidential. © 2023 Bio-Techne®. All rights reserved. | 29